A Retrospective Analysis of Ibrutinib-Associated Pneumonia

Authored by Rohan Ramnarain Tyrosine kinase inhibitors and their modulation of cancer cell proliferation may be associated with various adverse events serious enough to consider a change in therapy. Specifically, pneumonia rates among patients with cancer have been rising steadily for the last decade, perhaps due to increased use of stronger, sometimes immune modulating drugs such as ibrutinib. This particular agent targets Bruton’s tyrosine kinase, which is expressed most prominently in B cells, the cell from which most non-Hodgkin’s lymphomas and chronic lymphocytic leukemia originate.
The FDA has a publically available database that contains all adverse event reports from consumers, medwatch, and drug companies. This database is known as the FDA Adverse Event Reporting System (FAERS) and it contains over 10 million reports of adverse events that have been de-identified for safety of the patients reporting the adverse events. A subset of data from this database will look at the incidence rate of pneumonia in patients who took ibrutinib for mantle cell lymphoma, B-cell leukemia, and non-hodgkin’s lymphoma from 2010 through 2015. The incidence rate of pneumonia in ibrutinib will be compared to all other tyrosine kinase inhibitors to determine whether there is a significant increase of pneumonia incidence in ibrutinib compared to other tyrosine kinase inhibitors. A proportional t-test (p<0.05) will be used to determine significance.


Comments

Post a Comment

Popular posts from this blog

Controlling Informative Features for Improved Accuracy and Faster Predictions in Omentum Cancer Models

  Abstract Identification of suitable biomarkers for accurate prediction of phenotypic outcomes is a goal for personalized medicine. However, current machine learning approaches are either too complex or perform poorly. Here, a novel feature detection and engineering machine-learning framework is presented to address this need. First, the  Rip Curl  process is applied which generates a set of 10 additional features. Second, we rank all features including the  Rip Curl  features from which the top-ranked will most likely contain the most informative features for prediction of the underlying biological classes. The top-ranked features are used in model building. This process creates for more expressive features which are captured in models with an eye towards the model learning from increasing sample amount and the accuracy/time results. The performance of the proposed  Rip Curl  classification framework was tested on omentum cancer data.  Rip Curl  outperformed other more sophisticated
Read more

Biological Samples as a Tool for Analysis of Metals in Serum of Cataract Patients-Current Trends in Biomedical Engineering & Biosciences-Juniper Publishers

Image
JUNIPER PUBLISHERS-Current Trends in Biomedical Engineering & Biosciences Biological Samples as a Tool for Analysis of Metals in Serum of Cataract Patients Authored by Aima Iram Batool* There is much evidence suggesting that metallic elements may play a role in the formation or cure of human cataract, a disease that is on the increase due to the growing percentage of elderly persons in the world population.We have evaluated the levels of nickel, copper, cadmium, calcium, magnesium, lead and zinc in hairs and nail samples of cataractic subjects and compared these findings to the levels of healthy controls.A group of patients diagnosed with cataract and a group of healthy controls were chosen as subjects. Serum and hair samples were analyzed by atomic absorption spectrophotometry. Results were statistically evaluated by SPSS/PC software and student t-test.A significant difference was found in mean concentrations of metallic elements in comparison of patient group t
Read more

Research as a Tool in the Elimination of Onchocerciasis_Juniper Publishers

Image
Current Trends in Biomedical Engineering & Biosciences   Juniper Publishers Adewale B* Mini Review Onchocerciasis is one of the five diseases referred to as preventive chemotherapy- Neglected Tropical Diseases (PC-NTDs). It affects 37 million people in 31 African countries as well as 3 countries in the Latin America and several areas in Yemen. Nigeria has the highest endemicity among countries responsible for 99% of infection globally. Blindness and severe skin manifestations are two major effects of the disease on affected populations with severe effects on affected communities. The disease is significantly a disease of the poor with economic implications resulting in further impoverishment of affected communities, a challenge to the achievement of SDGs 2 and 3 and national developmental goals. The main strategy for control in endemic countries is by mass ivermectin (Mectizan®) distribution. Mass distribution of ivermectin in Nigeria began in 1991 following survey
Read more